Detalhe da pesquisa
1.
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis
; 20: 14799731231202257, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37800633
2.
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
Respir Res
; 20(1): 238, 2019 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31666084
3.
Long-term outcomes following first short-term clinically important deterioration in COPD.
Respir Res
; 19(1): 222, 2018 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30453972
4.
The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy.
Respir Res
; 13: 59, 2012 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22816878
5.
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD.
Respir Med
; 200: 106918, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35803172
6.
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial.
Int J Chron Obstruct Pulmon Dis
; 16: 1939-1956, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34234425
7.
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement.
Int J Chron Obstruct Pulmon Dis
; 16: 1215-1226, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33976543
8.
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.
ERJ Open Res
; 7(1)2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33718490
9.
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.
Ther Adv Respir Dis
; 14: 1753466620968500, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33167780
10.
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
Ther Adv Respir Dis
; 14: 1753466620926949, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32462979
11.
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting ß2-Agonist Therapy: An Integrated Post Hoc Analysis.
Adv Ther
; 35(10): 1626-1638, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30191464
12.
Post hoc analysis and claims of superiority in the EXCEL trial.
Respir Med
; 101(3): 681-2; author reply 683, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17166708
13.
Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control.
Chest
; 134(6): 1192-1199, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18689590